메디쿠스 파마MDCX 주가

Medicus Pharma Receives $22M In Non-Dilutive Financing

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today

♻️ 재탕[424B3] 424B3 — FORM 424B3

[8-K] 중대 사건 — FORM 8-K

Medicus Pharma sees catalyst-rich year ahead as SkinJect and Teverelix progress

Medicus Pharma (NASDAQ:MDCX) reported first quarter 2026 financial results on Thursday, highlighting progress across its SkinJect and Teverelix clinical programs while continuing efforts to strengthen its financing position. The biotech company said it recently reported positive expanded...

Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

Company Advances SkinJect® and Teverelix® Clinical Programs While Strengthening Financing Flexibility and Expanding Strategic Development InitiativesPHILADELPHIA, May 14, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today reported financial results for the three months ended March 31, 2026, and provided a corp

Medicus Pharma Q1 EPS $(0.31) Misses $(0.19) Estimate

Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.19) by 63.16 percent. This is a 26.19 percent increase over losses of $(0.42) per share from

[10-Q] 분기 실적 — FORM 10-Q

[424B3] 424B3 — FORM 424B3

EXCLUSIVE: Medicus Sees Strongest Efficacy At Higher Dose In Skin Cancer Study

Medicus Pharma Ltd. on Wednesday reported expanded Phase 2 SKNJCT-003 study data showing a clear dose-response relationship for its Doxorubicin Microneedle Array (D-MNA or SkinJect) for nodular basal cell carcinoma (BCC). The company said the pre-specified analysis builds on previously...

Medicus Pharma reports strong Phase 2 dose response in skin cancer study

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss new data from a pre-specified expanded dataset analysis of the company’s Phase 2 SKNJCT-003 clinical trial, highlighting a positive dose-response relationship for its Doxorubicin Microneedle Array in the treatment of nodular basal cell carcinoma, the most common form of skin cancer. Bokhari explained that the additional analysis builds on previously reported positive topline results, offering deeper biological, histologic, and safety insights that further strengthen the therapeutic profile of the company’s SkinJect platform. He noted that the findings are consistent with earlier clinical data, including results from the Phase 1 SKNJCT-001 study conducted in 2021 and interim Phase 2 data reported in March 2025, reinforcing the reproducibility and reliability of the treatment approach across multiple studies. The SKNJCT-003 trial was designed as a randomized, double-blind, three-arm Phase 2 study evaluating two different dose levels of microneedle-delivered doxorubicin compared to a device-only control. Conducted across multiple clinical sites, the study enrolled approximately 90 patients diagnosed with nodular basal cell carcinoma, aiming to assess both safety and efficacy in a controlled setting. According to Bokhari, the expanded dataset—verified through centralized pathology review—provides a clearer and more clinically meaningful picture of treatment outcomes. Among the cohorts, the 200-microgram dose at Day 57 emerged as the most promising, demonstrating the strongest and most consistent efficacy signal. These results suggest that the treatment may offer a non-surgical alternative for certain patients, potentially reducing or delaying the need for immediate excision of cancerous lesions. Such an approach could represent a meaningful shift in the standard treatment paradigm for BCC, particularly given the relatively short treatment and evaluation window used in the study. Bokhari added that the data package could support future registration-focused discussions with the U.S. Food and Drug Administration (FDA), including considerations around optimal dosing, patient selection, lesion subtype, and treatment timelines. The company believes these findings position SkinJect as a potentially innovative and practical therapeutic option in the dermatologic oncology space. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #ClinicalTrials #Phase2 #Biotech #Dermatology #SkinCancer #BasalCellCarcinoma #Microneedle #DrugDelivery #Oncology #MedicalInnovation #Healthcare #FDA #Biopharma